0000950170-24-037180.txt : 20240327
0000950170-24-037180.hdr.sgml : 20240327
20240327161007
ACCESSION NUMBER: 0000950170-24-037180
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240326
FILED AS OF DATE: 20240327
DATE AS OF CHANGE: 20240327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nguyen Alexander Hieu
CENTRAL INDEX KEY: 0001850065
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38470
FILM NUMBER: 24790708
MAIL ADDRESS:
STREET 1: C/O UNITY BIOTECHNOLOGY, INC.
STREET 2: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unity Biotechnology, Inc.
CENTRAL INDEX KEY: 0001463361
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 264726035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 416-1192
MAIL ADDRESS:
STREET 1: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cenexys, Inc.
DATE OF NAME CHANGE: 20130703
FORMER COMPANY:
FORMER CONFORMED NAME: Forge Inc
DATE OF NAME CHANGE: 20090504
4
1
ownership.xml
4
X0508
4
2024-03-26
0001463361
Unity Biotechnology, Inc.
UBX
0001850065
Nguyen Alexander Hieu
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Legal Officer
false
Common Stock, $0.0001 par value
2024-03-26
4
A
false
20000
0
A
25104
D
Stock Option (Right to Buy)
1.62
2024-03-26
4
A
false
30000
0
A
2034-03-25
Common Stock
30000
30000
D
Represents Restricted Stock Units ("RSUs") one quarter of which vests on March 26, 2025 with the remaining RSUs vesting in equal quarterly installments over a three year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Includes RSUs which vest over time measured from the grant date.
The underlying shares vest and become exercisable pursuant to the following schedule: One Fourth of the shares subject to the option vest on March 26, 2025 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
/s/ Alexander Hieu Nguyen
2024-03-27